Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

  title={Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials},
  author={Peter M. Rothwell and Jacqueline F. Price and F. Gerald R. Fowkes and Alberto Zanchetti and Maria Carla Roncaglioni and Gianni Tognoni and Robert J. Lee and Jill J.F. Belch and Michelle Wilson and Ziyah Mehta and Tom W Meade},
  journal={The Lancet},

Figures and Tables from this paper

Daily aspirin use and cancer mortality in a large US cohort.
Results are consistent with an association between recent daily aspirin use and modestly lower cancer mortality but suggest that any reduction in cancer mortality may be smaller than that observed with long-term aspirin use in the pooled trial analysis.
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial
Low-dose aspirin did not affect the risk for cardiovascular events but increased risk for gastrointestinal bleeding in patients with type 2 diabetes mellitus in a primary prevention setting.
Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
In older adults, aspirin treatment had an adverse effect on later stages of cancer evolution, suggesting that in older persons, aspirin may accelerate the progression of cancer and, thus, suggest caution with its use in this age group.
Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women
Conurrent evaluation of the absolute effects on cancer, CVD and major gastrointestinal bleeding showed that alternate-day use of low-dose aspirin is ineffective or harmful in the majority of women in primary prevention, but selective treatment of women ≥65 years with aspirin may improve net benefit.


Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomized trials
The possible effect of aspirin on reducing the risk of fatal cancer among patients with gastrointestinal and nongastrointestinal cancers was investigated, and the greatest benefit was found with scheduled duration of trial treatment of 7.5 years for solid cancers and gastrointestinal cancers.
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events.
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.
Results from this large-scale, long-term trial suggest that alternate day use of low-dose aspirin for an average 10 years of treatment does not lower risk of total, breast, colorectal, or other site-specific cancers.